VERA
Vera Therapeutics, Inc. (VERA) 10Y Growth Potential Analysis (2026)
Overall Score
Business Quality
VERA continues to show deeply negative profitability and returns, with ROA at -75.4%, ROE at -84.1%, and ROIC at -85.8%.
Margins remain effectively zero across gross, operating, EBITDA, pretax, and net profit lines, indicating no current earnings power.
Financial Strength
The balance sheet remains liquid, with a current ratio of 10.9x and cash ratio of 1.01x.
Leverage is modest, with debt-to-equity at 0.18x and debt-to-assets at 0.14x, while net debt to EBITDA is near flat at -0.07x.
Working capital is positive at $479.2M, supporting near-term flexibility despite weak operating cash generation.
Growth Runway
There is no visible revenue or margin expansion signal in the current metrics, with revenue per share reported at 0 and operating metrics still negative.
The company’s cash conversion cycle remains highly distorted at 6,106.9 days, suggesting no evidence of scalable operating momentum.
Valuation
Traditional earnings and cash-flow valuation multiples are not meaningful because EBITDA, operating cash flow, and free cash flow remain negative.
Book-based valuation is the main anchor, with price-to-book at 5.17x and price-to-fair-value at 5.17x, which does not indicate a clear deep-value setup.
Momentum
No recent news or fresh operating catalyst is present to improve the near-term setup.
The latest data still reflects a business with negative earnings and cash flow, limiting momentum visibility.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

